Previous 10 | Next 10 |
2024-06-05 07:17:36 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Biggest stock...
2024-06-04 17:32:04 ET More on psychedelic drug companies ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Psychedelic sto...
2024-05-31 10:43:44 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Mind Medicine...
2024-05-23 12:15:00 ET Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi disc...
Governor Wes Moore of Maryland recently signed two measures into law that will create a task force to conduct research on legal access to psychedelics such as DMT and psilocybin. This move comes almost a month after legislators forwarded the bills to the governor’s desk. The new law wi...
2024-05-21 08:05:00 ET As a psychedelic therapy developer, Compass Pathways (NASDAQ: CMPS) is on the cutting edge of innovation in treating mood disorders. That makes it an exciting, if quite risky, investment. But a lot of that risk burden could be alleviated soon, thanks to a ...
2024-05-11 17:31:10 ET COMPASS Pathways plc (CMPS) Q1 2024 Results Conference Call May 08, 2024 08:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants...
2024-05-10 00:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Depression is a leading cause of disability that affects roughly 300 million individuals around the globe. Now, new research has determined that psilocybin is an effective treatment for symptoms of depression. This is in comparison to niacin, which was administered as the placebo, and microdose...
2024-05-09 04:45:11 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q1 2024 Earnings Call May 08, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Tr...
News, Short Squeeze, Breakout and More Instantly...
2024-06-30 14:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment Latest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LO...
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5 th Annual Neuro Per...